Comparison of Interventions Made in an Ambulatory Pharmacist-Managed Refill Model to Usual Physician Care. (February 2020)

• Record Type: Journal Article
• Authors: Okraszewski, Stephanie; Sattler-Leja, Rebecca; Brodman, Monika; Goll, David; Lam, Simon W.
• Is Part Of: Journal of pharmacy technology. Volume 36:Number 1(2020)
• Page Start: 22
• Page End: 27
• Publication Date: 2020-02
• Subjects: clinical pharmacy -- pharmacist/physician issues -- prescribing patterns -- documentation interventions/outcomes -- internal medicine; Pharmacy -- Periodicals; Pharmaceutical technology -- Periodicals; Chemotherapy -- Periodicals; 615.105
• DOI: 10.1177/8755122519874686
• Languages: English
• ISSNs: 8755-1225

Abstract

Background: With the current practice model, there is less time for physicians to address refill authorization requests (RARs) while performing consistent quality care, which creates an opportunity for pharmacists to assist in refills. Currently, inadequate evidence is available to support this intervention.Objective: To compare the rate of medication management interventions (MMIs - drug therapy changes, laboratory monitoring ordered, or office visit scheduled) initiated by the pharmacist-managed authorization center (PMAC) to usual care.Methods: A retrospective, noninferiority study looked at 4000 RARs from 6 primary care centers from January 2016 through March 2017. The primary endpoint compared the rate of MMIs between PMAC and usual care. Noninferiority was concluded if the upper limit of the 95% CI of the difference in interventions was <2%. Secondary endpoints included total, type, and acceptance rate of PMAC recommendations.Results: A total of 3830 patients were included, with 4732 medications requested (2183 reviewed by PMAC and 2549 by usual care). MMIs occurred in 153 medications within PMAC (7.0%) versus 90 for usual care (3.5%). The difference in total MMIs between PMAC and usual care was −3.5% (95% confidence interval = −4.8% to −2.2%). Medications reviewed by PMAC had significantly higher number of laboratory monitoring ( P = .036) and scheduled appointments ( P < .001). There were 294 PMAC recommendations (13.5%) with a 52.0% acceptance rate.Conclusion and Relevance: This study showed that PMAC was superior to usual care for reviewing RARs. There was a statistically significant improvement in medication monitoring and patient follow-up, supporting the idea of including a pharmacist in the decision making.